I. Abstract
Changes in technology, regulatory guidance, and COVID-19 have spurred an explosion in online studies in the social and clinical sciences. This surge has led to a need for brief and accessible instruments that are designed and validated specifically for self-administered, online use. Addressing this opportunity, the Brief Attention and Mood Scale of 7 Items (BAMS-7) was developed and validated in five cohorts across four studies to assess real-world attention and mood in one instrument. In Study 1, an exploratory factor analysis was run on responses from an initial nine-item survey in a very large, healthy, adult sample (N=75,019, ages 18-89 years). Two brief subscales comprising seven items total were defined and further characterized: one for Attention, the other for Mood. Study 2 established convergent validity with existing questionnaires in a separate sample (N=150). Study 3 demonstrated known-groups validity of each subscale using a large sample (N=58,411) of participants reporting a lifetime diagnosis of ADHD, anxiety, or depression, alongside the healthy sample of Study 1. The Attention subscale had superior discriminability for ADHD and the Mood subscale for anxiety and depression. Study 4 applied confirmatory factor analysis to data (N=3,489) from a previously published cognitive training study that used the initial nine-item survey, finding that the Attention and Mood subscales were sensitive to the intervention (compared to an active control) to different degrees. In sum, the psychometric properties and extensive normative data set (N=75,019 healthy adults) of the BAMS-7 may make it a useful instrument in assessing real-world attention and mood.
Competing Interest Statement
This study was supported entirely by Lumos Labs, Inc. At the time of the study, KPM, AMO, KRK, and RJS were paid employees of the company, and all hold stock in the company.
Funding Statement
No grants were received for conducting this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Western Institutional Review Board-Copernicus Group (WCGB IRB) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The text of the manuscript was revised to incorporate changes.
Data Availability
Aggregations of the data (i.e., norm tables) appear in the text, along with the BAMS-7 scale itself. Descriptions of the computer programming packages used to conduct the analyses are contained in the text.
